Daniel Geynisman, MD

Daniel M. Geynisman, MD
157 Patient Satisfaction Ratings
Request an Appointment

Clinical Locations

Chief, Division of Genitourinary Medical Oncology

Associate Professor, Department of Hematology/Oncology

Vice Chair, Quality Improvement Program

NCCN, Testicular Cancer Panel Member

Treatment Focus

Chemotherapy, targeted therapy, immunotherapy, hormone therapy, clinical trials for genitourinary malignancies

Key Awards

Philadelphia Magazine Top Docs 2022
Medical Oncology

Treatment Philosophy

I am a medical oncologist specializing in genitourinary cancers.  I became a physician and an oncologist for many reasons including the ability to sometimes cure life-threatening illness, having the opportunity to care for ill patients, and being a part of a rapidly evolving and improving field.  But perhaps the most important reason for entering oncology for me was the chance to build deep relationships with patients and their families at a time when they are the most vulnerable and in need, to be their advocate and resource, to guide them through a grueling time and hope with them for the best.  

I believe that every cancer patient deserves the utmost compassionate, individualized, expert and prompt care.  I came to Fox Chase after completing my fellowship at the University of Chicago because here I can offer just that. By working together with each patient, their family and a team of my expert colleagues, we can harness the most recent advances in oncology for each patient.

In my clinical practice I focus on the care of patients with prostate, kidney, bladder, penile, adrenal and testicular cancer and I am proud to be part of a large multidisciplinary team of distinguished clinicians and researchers at Fox Chase.  Over the last decade, the number of treatment options for patients with advanced cancers has greatly expanded and at Fox Chase we can offer both the latest standard-of-care as well as new experimental approaches. My particular research interest is in health outcomes as well as clinical trials development for genitourinary cancers.

A cancer diagnosis is one of the most difficult times in a person’s life; my primary goal is to bring together all the resources of a cutting-edge cancer center to the patient in a compassionate and individualized manner.

Educational Background

  • Fellow, Maclean Center for Clinical Medical Ethics, University of Chicago, Chicago, IL
  • Fellow and Chief Fellow, Hematology and Medical Oncology, University of Chicago Medical Center, Chicago, IL
  • Intern, Resident and Chief Resident, University of Pittsburgh Medical Center, Pittsburgh, PA
  • MD, University of Pittsburgh, Pittsburgh, PA, 2006


  • American Board of Internal Medicine, Medical Oncology, 2013 
  • American Board of Internal Medicine, 2009   


  • American Society of Clinical Oncology

Honors & Awards

  • ASCO/AACR Methods in Clinical Research Workshop Selected Participant, Vail, CO, 2014   
  • Illinois Medical Oncology Society Fellows Award, Chicago, Illinois, 2012 
  • Senior Presentation Award, University of Pittsburgh School of Medicine Department of  Medicine, 2009   
  • Lucien J. Rubenstein Memorial Award, American Brain Tumor Association, 2003 
  • Morris H. and Gertrude M. Harris Foundation Scholarship, University of Pittsburgh School of Medicine, Pittsburgh, PA, 2002–2006

Mahmood Saeed

  • Kidney Cancer

After being diagnosed with Stage 4 renal cell carcinoma, Mahmood Saeed sought treatment at Fox Chase Cancer Center. Prior to Fox Chase, other doctors only gave him a 5 percent chance of survival, but Fox Chase gave him hope. Today he takes a daily targeted therapy to keep the tumors from spreading; this treatment has greatly improved his quality of life. "I wouldn’t be here today without Dr. Reddy, my wife, and my faith," Mahmood said. "For my family, it wasn’t just one procedure or one doctor that led to healing—rather, it was the culmination of a healthy diet, support from family and friends, a positive attitude, and doctors working together as a team."


James Tetzlaff

  • Kidney Cancer

When he thinks back on October 28, 2013, Jim Tetzlaff realizes it would have been easy to ignore what happened and not give it another thought. “I’m a man – we have a tendency to ignore things that have to do with our health,” says Jim, who was 75 at the time. On that day, after one of his grandson’s football games, Jim went to the bathroom and saw blood in his urine. “It was upsetting, but I didn’t have any other symptoms so I thought it had to be a fluke,” recalls the former medical equipment salesman.


Research Interests

  • Drug development for genitourinary malignancies
  • Health outcomes/services research
  • Medical ethics

Selected Publications

Geynisman D.M., Du E.X., Yang X., Sendhil S.R., Tejo V.D., Betts K.A.,Huo S., Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma. Future Oncol. 18(10): 1219-1234, 2022.  https://www.ncbi.nlm.nih.gov/pubmed/34939424.

Geynisman D.M., Kadow B.T., Shuch B.M., Boorjian S.A., Matin S.F., Rampersaud E., Milestone B.N., Plimack E.R., Zibelman M.R., Kutikov A., Smaldone M.C., Chen D.Y., Viterbo R., Joshi S., Greenberg R.E., Malizzia L., McGowan T., Ross E.A.,Uzzo R.G., Sporadic angiomyolipomas (amls) growth kinetics while on everolimus (sage): Results of a phase ii trial. J Urol. 204(3): 531-537, 2020. PMC7695484. https://www.ncbi.nlm.nih.gov/pubmed/32250730.

Strother M.C., Kutikov A., Epstein M., Bochner E., Deng M., Handorf E., Lewis B., Ghatalia P., Greenberg R.E., Chen D., Viterbo R., Anari F., Smaldone M.C., Zibelman M.R., Uzzo R.G., Plimack E.R., Geynisman D.M., Safety of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer and malignant ureteric obstruction. BJU Int. 129(3): 364-372, 2022. https://www.ncbi.nlm.nih.gov/pubmed/33780097.

Changa NM, Xie WL, Bilen MA, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncology, 20(4):581-90, 2019.

Rouvinov K, Plimack ER, Zibelman M, Ghatalia P, Geynisman DM. Update on perioperative systemic therapy for urothelial carcinoma. Clinical advances in hematology & oncology : H&O, 17(3):176-83, 2019.

Martinez Chanza N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. The Lancet Oncology, 2019.

Correa AF, Handorf E, Joshi SS, Geynisman DM, Kutikov A, Chen DY, Uzzo RG, Viterbo R, Greenberg RE, Smaldone MC. Differences in Survival Associated with Performance of Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from the National Cancer Database. J Urol, 199(5):1238-44, 2018. PubMed

Geynisman DM, Abbosh PH, Plimack ER, Zibelman M. Chemoimmunotherapy in Metastatic Urothelial Carcinoma. Eur Urol, 2018. 

Joshi SS, Handorf E, Strauss D, Correa AF, Kutikov A, Chen DYT, Viterbo R, Greenberg RE, Uzzo RG, Smaldone MC, Geynisman DM. Treatment Trends and Outcomes for Patients With Lymph Node-Positive Cancer of the Penis. JAMA Oncol, 2018. 

Geynisman DM, Ross EA, Plimack ER. Osteoclast Inhibitors in Advanced Prostate Cancer: Does the Benefit Extend Beyond Skeletal-Related Events? Eur Urol. 2015 Oct;68(4):578-80. doi: 10.1016/j.eururo.2015.06.009. Epub 2015 Jun 23. PubMed

Seeger-Nukpezah T, Geynisman DM, Nikonova AS, Benzing T, Golemis EA. The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease. Nat Rev Nephrol. 2015 Sep;11(9):515-34. doi: 10.1038/nrneph.2015.46. Epub 2015 Apr 14. Review. PubMed

Geynisman DM. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol. 2015 Jul 17. pii: S0302-2838(15)00612-0. doi: 10.1016/j.eururo.2015.07.008. [Epub ahead of print] PubMed

Shih YC, Smieliauskas F, Geynisman DM, Kelly RJ, Smith TJ. Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011. J Clin Oncol. 2015 Jul 1;33(19):2190-6. doi: 10.1200/JCO.2014.58.2320. Epub 2015 May 18. PubMed PMID: 25987701; PubMed Central PMCID: PMC4477789.  PubMed

Geynisman DM, Szmulewitz RZ, Plimack ER. Corticosteroids and prostate cancer: friend or foe? Eur Urol. 2015 May;67(5):874-5. doi: 10.1016/j.eururo.2014.08.008. Epub 2014 Aug 20. PubMed

Geynisman DM, Hu JC, Liu L, Tina Shih YC. Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States. Clin Genitourin Cancer. 2015 Apr;13(2):e93-100. doi: 10.1016/j.clgc.2014.08.013. Epub 2014 Sep 28. PubMed

Barth P, Dulaimi Al-Saleem E, Edwards KW, Millis SZ, Wong YN, Geynisman DM. Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature. Case Rep Oncol Med. 2015;2015:895151. doi: 10.1155/2015/895151. Epub 2015 Jan 27. PubMed PMID: 25692060; PubMed Central PMCID: PMC4322830.   PubMed

Godwin JL, Zibelman M, Plimack ER, Geynisman DM. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials. Discov Med. 2014 Dec;18(101):341-50. PubMed

Smieliauskas F, Chien CR, Shen C, Geynisman DM, Shih YC. Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review. Pharmacoeconomics. 2014 Jul;32(7):651-80. doi: 10.1007/s40273-014-0160-z. Review. PubMed

Shen C, Chien CR, Geynisman DM, Smieliauskas F, Shih YC. A review of economic impact of targeted oral anticancer medications. Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):45-69. doi: 10.1586/14737167.2014.868310. Epub 2013 Dec 30. Review. PubMed

Geynisman DM, Chien CR, Smieliauskas F, Shen C, Shih YC. Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review. Hum Vaccin Immunother. 2014;10(11):3415-24. doi: 10.4161/hv.29407. PubMed

Additional Publications

157 patient satisfaction reviews

Our Patient Satisfaction Rating is an average of all responses to care provider related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Learn more.

Overall Rating

4.9 / 5.0

Ratings Breakdown

Gives easy to understand instruction
Explains in a way you understand
Listens carefully to you
Shows respect for what you say
Spends enough time with you

22 patient comments

  • 5.0
    March 28, 2022

    Very caring and thoughtful

  • 5.0
    March 21, 2022

    Excellent care

  • 5.0
    March 16, 2022

    Everyone was courteous,knowledgeable, and professional!

  • No Star Ratings Available
    February 28, 2022

    Dr. G. Is the BEST! His calm demeanor is exactly what is needed, and appreciated by a cancer patient.

  • 5.0
    November 26, 2021

    Treatment by Dr Geynisman is always excellent, professional, unhurried, thorough

  • 5.0
    November 16, 2021

    Dr. Geynisman was patient and thorough in relating the results of my tests. I appreciated that he told me right away that there was no change.

  • 5.0
    November 2, 2021

    Dr. Geynisman and his staff are always thorough.

  • 5.0
    October 24, 2021

    I am very happy with care I receiving from my doctor and all his team

  • 5.0
    October 22, 2021

    Good experience. I am appreciate for your service.

  • No Star Ratings Available
    October 6, 2021

    Dr. Geynisman is fantastic as a physician, as an oncologist and as a partner in my battle with cancer. He explain things well. He listens actively and answers my questions expertly in an understandable manner. I would highly recommend Dr. Geynisman as an oncologist to any other patient facing or in the thick of the battle with prostate cancer.

  • 5.0
    September 24, 2021

    Excellent care excellent staff. Fox Chase also an excellent Hospital!

  • 5.0
    September 24, 2021

    Dr. Geynisman has a fantastic "bed side" manner. He is very friendly, personable and has a great sense of humor.

  • 5.0
    August 12, 2021

    I love the care given to me by Dr. Geynisman & his staff. I am so glad to be under his care.

  • 5.0
    July 29, 2021

    Dr Daniel Geynisman and [...] are excellent medical providers.

  • 5.0
    May 24, 2021

    I always feel in good hands with this provider

  • 5.0
    May 18, 2021

    Excellent visit, staff always caring, professional and thorough.

  • 5.0
    April 30, 2021

    excellent care.

  • 5.0
    April 12, 2021

    Dr. Geynisman is a great dr. Would recommend to anyone.

  • 5.0
    March 12, 2021

    Dr. Geynisman is always forth coming in discussions, recommendations; always professional, knowledgeable and very pleasant.

  • 5.0
    February 19, 2021

    Dr Geynisman is exceptional. He truly cares for his patients - not just their disease but their well-being. it's like my Oncologst is a good friend, who just happens to be an incredible oncologist.

  • 5.0
    January 29, 2021

    Always a great experience. Phenomenal physician and staff.

  • 5.0
    January 8, 2021

    Dr. Geynisman is without a doubt one of the finest dr.'s ever [...].